440 related articles for article (PubMed ID: 28752255)
1. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
Fanning L; Ilomäki J; Bell JS; Dārziņš P
Eur J Clin Pharmacol; 2017 Nov; 73(11):1427-1436. PubMed ID: 28752255
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?
Desmaele S; Steurbaut S; Cornu P; Brouns R; Dupont AG
Eur J Clin Pharmacol; 2016 Sep; 72(9):1125-34. PubMed ID: 27272167
[TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
4. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
6. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
8. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
9. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
14. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
[TBL] [Abstract][Full Text] [Related]
16. Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF.
Himmelreich JCL; Virdone S; Camm J; Pieper K; Harskamp RE; Oto A; Jacobson BF; Sawhney JPS; Lim TW; Gibbs H; Goto S; Haas S; Fox KAA; Jansky P; Verheugt F; Kakkar AK;
Open Heart; 2024 Jul; 11(2):. PubMed ID: 38955399
[TBL] [Abstract][Full Text] [Related]
17. Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
Grant SJ; Kothari S; Gimotty PA; Gooneratne NS; Cuker A
J Thromb Thrombolysis; 2018 Jul; 46(1):1-6. PubMed ID: 29611105
[TBL] [Abstract][Full Text] [Related]
18. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Hess CN; Al-Khatib SM; Granger CB; Lopes R
Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
[TBL] [Abstract][Full Text] [Related]
19. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
[TBL] [Abstract][Full Text] [Related]
20. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
